Biocon Biologics is a unique, fully integrated, global biosimilars company committed to transforming healthcare by enabling affordable access to high quality biosimilars for millions of patients worldwide. The Company specializes in developing, manufacturing, and commercializing a differentiated and comprehensive biosimilars portfolio including insulins, monoclonal antibodies and conjugated recombinant proteins. By focusing on accessibility and affordability, the Company is bridging the disparities that exist between high-income countries and low- and middle-income countries (LMlCs) in terms of access to cutting-edge biologic therapies.
*Download without consent